6-K - RDY - Equibles

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

ExhibitNumber	Description of Exhibits
99.1	Intimation dated March 10, 2026
2
---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED<br><br>(Registrant)
Date: March 10, 2026	By:	/s/ K Randhir Singh
		Name: K Randhir Singh
		Title: Company Secretary
3
---

Exhibit 99.1

Dr. Reddy's Laboratories Ltd.<br><br>8-2-337, Road No. 3, Banjara Hills<br><br>Hyderabad – 500 034, Telangana, India<br><br><br><br>CIN: L85195TG1984PLC004507<br><br><br><br>Tel: + 91 40 4900 2900<br><br>Fax: + 91 40 4900 2999<br><br>Email: mail@drreddys.com<br><br>Web: www.drreddys.com

March 10, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub:	Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Change in Senior Managerial Personnel

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that, based on the recommendation of the Nomination, Governance and Compensation Committee, the Board of Directors of the Company has today, approved elevation of Mr. M S Madhu Sundar, currently serving as Head Global Manufacturing FTO Oral Solid Dosages (OSD) & Operational Excellence (OE), by appointing him as Global Head of Quality and PV and Senior Management Personnel of the Company and has also inducted him as a Member of Management Council, effective from April 1, 2026.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in Annexure A.

In addition to the above, changes in role/designation of certain Senior Management Personnel of the Company are enclosed as Annexure B.

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR

Encl: as above

Annexure - A

Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise;~~	Mr. M S Madhu Sundar is being elevated as Global Head of Quality and PV, Senior Management Personnel and Member of Management Council of the Company with effect from April 01, 2026<br><br><br><br>Terms of appointment: Full-time employment
2	Date of appointment/~~re-appointment/cessation (as applicable)~~ & term of appointment/~~re-appointment~~
3	Brief profile (in case of appointment)	M S Madhu Sundar serves as the Head of Formulation Manufacturing of 7 OSD units of the Global Manufacturing Organization of the company. He also has the additional role of leading the Operations Excellence program of the Global Manufacturing Organization. Madhu Sundar is a post graduate in Chemistry and possesses a M. Tech degree in advanced analytical chemistry from IIT Delhi. He possesses significant experience in API and dosage form manufacturing and has handled assignments in manufacturing, quality management, regulatory affairs and supply chain in his 28 years of industrial experience. He joined the company in October 2017 as a site head and has since assumed positions of increasing responsibilities within the company. He has been in his current role since Dec 2023.
4	Disclosure of relationships between directors<br><br>(in case of appointment of a director)	Not applicable

Annexure – B: Details of Change in role/designation of the following Senior Management Personnel of the Company, effective from April 1, 2026 ****

Name of the Senior Management Personnel	Revised Role/Designation
Mr. M V Ramana	CEO Global Generics
Mr. Sanjay Sharma	Chief Operating Officer
Mr. Krishna Venkatesh	Global Head of IPDO, Integrated Product Development
Mr. Patrick Aghanian	Head - Consumer Health Organization